Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
Cash Flows From Operating Activities | |||||
Net Income | 2,675,000 | 3,843,000 | 1,968,000 | 5,460,000 | 5,457,000 |
Depreciation Amortization | 1,054,000 | 707,000 | 359,000 | 1,429,000 | 1,071,000 |
Income taxes - deferred | -796,000 | 28,000 | 24,000 | 289,000 | 10,000 |
Accounts receivable | 33,000 | -68,000 | 32,000 | 480,000 | 367,000 |
Accounts payable and accrued liabilities | -142,000 | -166,000 | -201,000 | -39,000 | -217,000 |
Other Working Capital | -986,000 | -1,094,000 | -893,000 | -939,000 | -1,167,000 |
Other Operating Activity | 4,726,000 | 669,000 | 288,000 | 1,720,000 | 534,000 |
Operating Cash Flow | $6,564,000 | $3,919,000 | $1,577,000 | $8,400,000 | $6,055,000 |
Cash Flows From Investing Activities | |||||
Change In Deposits | -1,896,000 | -5,429,000 | 364,000 | 15,625,000 | 12,436,000 |
PPE Investments | -622,000 | -422,000 | -237,000 | -924,000 | -676,000 |
Net Acquisitions | -4,251,000 | -239,000 | N/A | N/A | N/A |
Purchase Of Investment | -1,251,000 | -104,000 | -56,000 | -156,000 | -132,000 |
Other Investing Activity | -228,000 | -213,000 | -315,000 | -190,000 | -8,000 |
Investing Cash Flow | $-8,248,000 | $-6,407,000 | $-244,000 | $14,355,000 | $11,620,000 |
Cash Flows From Financing Activities | |||||
Debt Repayment | -2,750,000 | -1,250,000 | -750,000 | -6,250,000 | -6,250,000 |
Common Stock Issued | 182,000 | 141,000 | 103,000 | 289,000 | 239,000 |
Common Stock Repurchased | -1,644,000 | -1,422,000 | -834,000 | -2,900,000 | -1,938,000 |
Dividend Paid | -2,421,000 | -1,617,000 | -817,000 | -2,971,000 | -2,235,000 |
Other Financing Activity | -105,000 | -75,000 | -68,000 | -486,000 | -464,000 |
Financing Cash Flow | $-6,738,000 | $-4,223,000 | $-2,366,000 | $-12,318,000 | $-10,648,000 |
Exchange Rate Effect | -44,000 | 11,000 | 20,000 | -85,000 | -46,000 |
Beginning Cash Position | 17,940,000 | 17,940,000 | 17,940,000 | 7,588,000 | 7,588,000 |
End Cash Position | 9,474,000 | 11,240,000 | 16,927,000 | 17,940,000 | 14,569,000 |
Net Cash Flow | $-8,466,000 | $-6,700,000 | $-1,013,000 | $10,352,000 | $6,981,000 |
Free Cash Flow | |||||
Operating Cash Flow | 6,564,000 | 3,919,000 | 1,577,000 | 8,400,000 | 6,055,000 |
Capital Expenditure | -622,000 | -422,000 | -237,000 | -924,000 | -676,000 |
Free Cash Flow | 5,942,000 | 3,497,000 | 1,340,000 | 7,476,000 | 5,379,000 |